These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 33007521)

  • 1. Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment.
    Baumal CR; Bodaghi B; Singer M; Tanzer DJ; Seres A; Joshi MR; Feltgen N; Gale R
    Ophthalmol Retina; 2021 Jun; 5(6):519-527. PubMed ID: 33007521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
    Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
    Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.
    Baumal CR; Spaide RF; Vajzovic L; Freund KB; Walter SD; John V; Rich R; Chaudhry N; Lakhanpal RR; Oellers PR; Leveque TK; Rutledge BK; Chittum M; Bacci T; Enriquez AB; Sund NJ; Subong ENP; Albini TA
    Ophthalmology; 2020 Oct; 127(10):1345-1359. PubMed ID: 32344075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intraocular inflammation with brolucizumab use : Patient management-diagnosis-therapy].
    Holz FG; Heinz C; Wolf A; Hoerauf H; Pleyer U
    Ophthalmologe; 2021 Mar; 118(3):248-256. PubMed ID: 33555415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER.
    Singer M; Albini TA; Seres A; Baumal CR; Parikh S; Gale R; Kaiser PK; Lobach I; Feltgen N; Joshi MR; Ziemssen F; Bodaghi B
    Ophthalmol Retina; 2022 Feb; 6(2):97-108. PubMed ID: 33971353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of brolucizumab in neovascular age-related macular degeneration: A multicentre retrospective real-world study.
    Kim DJ; Kim DG; Kwak HD; Jang JY; Ji YS; Lee SH; Lee EK; Park KH; Kim JH; Lee JS; Song Y; Kim ST; Shin MH; Kim M; Park SJ; Joo K; Sagong M; Lee CS; Woo SJ
    Acta Ophthalmol; 2024 Nov; 102(7):e1018-e1028. PubMed ID: 38706195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection and Management of Intraocular Inflammation after Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration.
    Bodaghi B; Souied EH; Tadayoni R; Weber M; Ponthieux A; Kodjikian L
    Ophthalmol Retina; 2023 Oct; 7(10):879-891. PubMed ID: 37343623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map.
    Khanani AM; Zarbin MA; Barakat MR; Albini TA; Kaiser PK; B G; Agashivala N; Yu JS; Wykoff CC; MacCumber MW
    JAMA Ophthalmol; 2022 Jan; 140(1):20-28. PubMed ID: 34817566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central retinal artery occlusion after intravitreal brolucizumab injection for treatment-naïve neovascular age-related macular degeneration; a case report.
    Hong SH; Kim HD
    BMC Ophthalmol; 2024 Apr; 24(1):200. PubMed ID: 38679743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.
    Enríquez AB; Baumal CR; Crane AM; Witkin AJ; Lally DR; Liang MC; Enríquez JR; Eichenbaum DA
    JAMA Ophthalmol; 2021 Apr; 139(4):441-448. PubMed ID: 33630045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD.
    Khoramnia R; Figueroa MS; Hattenbach LO; Pavesio CE; Anderesi M; Schmouder R; Chen Y; de Smet MD
    Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1843-1856. PubMed ID: 34932153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy.
    Kataoka K; Horiguchi E; Kawano K; Ushida H; Nakano Y; Ito Y; Terasaki H
    Jpn J Ophthalmol; 2021 Mar; 65(2):199-207. PubMed ID: 33543352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Patient Selection, Evaluation, and Treatment.
    Holz FG; Iida T; Maruko I; Sadda SR
    Retina; 2022 Sep; 42(9):1629-1637. PubMed ID: 35994582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Swept-source optical coherence tomography angiography of retinal occlusive vasculitis following brolucizumab administration: a case report.
    Lee EK; Oh BL; Yoon CK; Park UC
    BMC Ophthalmol; 2022 Jun; 22(1):244. PubMed ID: 35659269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
    Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
    Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN: A Multicenter Age-Related Macular Degeneration Study.
    Inoda S; Takahashi H; Maruyama-Inoue M; Ikeda S; Sekiryu T; Itagaki K; Matsumoto H; Mukai R; Nagai Y; Ohnaka M; Kusuhara S; Miki A; Okada AA; Nakayama M; Nishiguchi KM; Takeuchi J; Mori R; Tanaka K; Honda S; Kohno T; Koizumi H; Miyara Y; Inoue Y; Takana H; Iida T; Maruko I; Hayashi A; Ueda-Consolvo T; Yanagi Y
    Retina; 2024 Apr; 44(4):714-722. PubMed ID: 38016089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-Term Safety and Efficacy of Intravitreal Brolucizumab Injections for Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Real-World Study.
    Kim DJ; Jin KW; Han JM; Lee SH; Park YS; Lee JY; Lee EK; Lee JS; Kim ST; Shin MH; Lee CS; Jung HH; Jang JY; Kim M; Kim YH; Kim JH; Park KH; Park SJ; Joo K; Ji YS; Sagong M; Woo SJ
    Ophthalmologica; 2023; 246(3-4):192-202. PubMed ID: 36720210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular adverse events following intravitreal brolucizumab for neovascular age-related macular degeneration at a single tertiary care center.
    Nguyen HV; Li AS; Silva AR; Leng T
    Eur J Ophthalmol; 2022 Sep; 32(5):2747-2751. PubMed ID: 34761684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EXUDATIVE RETINAL DETACHMENT AFTER INTRAVITREAL BROLUCIZUMAB INJECTION.
    Betsch DM; Sarraf D; Francisconi CLM
    Retin Cases Brief Rep; 2023 Jul; 17(4):463-465. PubMed ID: 36893333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema.
    Hirano T; Toriyama Y; Takahashi Y; Hoshiyama K; Murata T
    Am J Ophthalmol Case Rep; 2023 Mar; 29():101788. PubMed ID: 36632338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.